NEW DRUGS IN NON-HODGKINS-LYMPHOMA

While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeut ic results, cytotoxic therapy remains the mainstay of therapy. Several new chemotherapy agents, including purine antimetabolites, taxanes, c amptothecins, suramin, and protein kinase C inhibitors, are discussed. Other issues important in lymphoma drug development, including the li mited patient population available for evaluation of investigational a gents, are also considered.